FDA approves Arcutis Biotherapeutics’ ZORYVE for pediatric and adult atopic dermatitis
In a significant development for the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the U.S. Food and Drug Administration (FDA) approval ... Read More
Arcutis Biotherapeutics gets ZORYVE FDA approval for seborrheic dermatitis
Arcutis Biotherapeutics, Inc., a pioneer in immuno-dermatology, has announced the U.S. Food and Drug Administration's (FDA) approval of their new drug application for ZORYVE (roflumilast) ... Read More